8-K: TransCode Amends Preferred Stock Terms for Nasdaq Compliance

TransCode Therapeutics, Inc. filed an amended certificate of designation for its Series A and B Preferred Stock, clarifying conversion limits and removing delisting conversion rights to comply with Nasdaq rules.

Summary

• An Amended and Restated Certificate of Designation for Series A and Series B Non-Voting Convertible Preferred Stock was filed on October 27, 2025.
• The amendment clarifies that TransCode Therapeutics, Inc. will not issue more than an aggregate of 19.9% of its Common Stock outstanding as of October 8, 2025, pursuant to the Purchase Agreement and Section 6.1.1, prior to obtaining stockholder approval.
• The ability for Preferred Stock holders to convert their shares into Common Stock at their option in the event of a Nasdaq delisting has been removed.
• These changes were approved by a majority of the Preferred Stock holders and the company's Board of Directors.
• The company expects to file a proxy statement with the SEC to seek stockholder approval for the conversion of Preferred Stock into Common Stock and for a change of control under Nasdaq listing rules.

Sentiment

Score: 6

Explanation: The filing represents a necessary procedural step to ensure compliance with Nasdaq listing rules for previously issued preferred stock. While the removal of a conversion right upon delisting is a minor negative for preferred holders, the overall action is a positive for corporate governance and facilitating a larger transaction. It's not a major positive or negative event in itself, but a step towards clarity and compliance.

Positives

• Procedural steps were taken to ensure compliance with Nasdaq listing rules regarding the conversion of Preferred Stock and a potential change of control, which is positive for corporate governance.
• The Board of Directors and a majority of Preferred Stock holders approved the amendments, indicating internal alignment on these changes.

Negatives

• The removal of the option for Preferred Stock holders to convert their shares into Common Stock upon Nasdaq delisting removes a potential protective right for these holders.
• The 19.9% issuance cap prior to stockholder approval could delay the full conversion of Preferred Stock, impacting liquidity for holders.

Risks

• Failure to obtain stockholder approval for the conversion of Preferred Stock into Common Stock and the change of control proposal could impact the underlying Membership Interest Purchase Agreement and Investment Agreement.
• The Beneficial Ownership Limitation, initially set at 9.99%, restricts immediate full conversion for holders, potentially limiting their ability to realize value.
• There is a risk of cash settlement or a 'Buy-In' if the company fails to timely deliver Common Stock upon conversion, which could result in additional costs for the company or holders.

Future Outlook

The company expects to file a proxy statement with the SEC to seek stockholder approval for the conversion of Preferred Stock into Common Stock and for a change of control, both necessary to comply with Nasdaq listing rules.

Management Comments

• The filing of the Amended and Restated Certificate of Designation was intended to amend and restate the terms mentioned above, and no additional securities were issued or sold as a result.

Industry Context

This filing reflects a common practice in corporate finance where companies adjust the terms of convertible securities to ensure compliance with exchange listing rules, particularly when significant transactions, such as the underlying Membership Interest Purchase Agreement and Investment Agreement, involve potential changes in control or substantial equity issuance. Such amendments are crucial for maintaining market integrity and investor confidence in listed companies.

Comparison to Industry Standards

• The 19.9% issuance cap prior to stockholder approval is a standard Nasdaq listing rule (Rule 5635) designed to prevent significant dilution or changes in control without prior shareholder consent. Many companies undertaking similar transactions must adhere to this threshold.
• The beneficial ownership limitation, initially set at 9.99%, is a common provision in convertible securities. It aims to prevent a single holder from exceeding certain ownership thresholds, often to avoid triggering specific regulatory filings or change of control provisions.
• The removal of the delisting conversion right is a specific amendment to this company's preferred stock terms, which may differ from other preferred stock agreements depending on their specific negotiated terms and the company's risk profile.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Potential for future dilution upon conversion of preferred stock, but the 19.9% cap prior to approval provides a temporary safeguard. They will be asked to vote on conversion and change of control proposals.
• Preferred Stock Holders: Loss of the option to convert upon Nasdaq delisting. Their conversion is subject to stockholder approval and beneficial ownership limitations. Series A holders are entitled to PIK dividends.
• Nasdaq: The amendments aim to ensure compliance with its listing rules, which is important for maintaining the company's listing status.

Next Steps

• The company will file a proxy statement with the SEC for stockholder approval of the conversion of Preferred Stock into Common Stock.
• The company will file a proxy statement with the SEC for stockholder approval of a change of control under Nasdaq Listing Rules.
• A definitive proxy statement will be sent to all Company stockholders as of the record date to be established for the shareholder meeting.

Key Dates

Recommendation

This filing details procedural amendments to the terms of existing preferred stock, primarily to ensure compliance with Nasdaq listing rules for a previously announced transaction. It does not introduce new financial performance data or strategic shifts that would warrant a change in investment thesis. While the removal of a conversion right upon delisting is a minor negative for preferred holders, the overall action is a necessary step for corporate governance and facilitating the underlying Purchase and Investment Agreements. Investors should await the proxy statement and the outcome of the stockholder vote for more significant insights into the transaction's progression.

Keywords

TransCode Therapeutics, RNAZ, SEC Filing, 8-K, Preferred Stock, Convertible Stock, Nasdaq Compliance, Corporate Governance, Stockholder Approval, Certificate of Designation, DEFJ LLC